PerkinElmer has launched its latest AlphaLISA SureFire ultra assays which offer a reduction in assay time.
Life sciences firm PerkinElmer has unveiled its latest ultra assays which are designed to reduce assay time by up to 50% and to improve the protein phosphorylation detection process.
According to PerkinElmer, this is critical for helping life science professionals to obtain more accurate results in biotherapeutic drug discovery research.
With high sensitivity and wide dynamic range to detect protein phosphorylation, even at low levels, AlphaLISA SureFire Ultra assays are quick and easy to run with a minimal amount of sample, significantly reducing time and expense.
Researchers can use the assays to analyse cell lysates or tissue lysates, whether they are treated with therapeutic antibodies or small molecules.
The AlphaLISA SureFire Ultra assays use TGR BioSciences’ CaptSure technology to eliminate antibody interference in the therapeutic antibody screening process.
The assays also leverage PerkinElmer’s AlphaLISA technology that has better spectral characteristics related to hemoglobin interference, which can otherwise hinder the accuracy of measurements.
AlphaLISA SureFire Ultra generates results in less than three hours with minimal incubation steps and no washing. Researchers can analyse different endogenous or transfected targets in parallel - all on the same plate.
